Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS)

Chi tiết về thư mục
Những tác giả chính: van der Heijde, D, Dijkmans, B, Schiff, M, Kivitz, A, de Vlam, K, Wordsworth, P, Ballal, S, Kupper, H, Wong, R, Sieper, J, Grp, A
Định dạng: Conference item
Được phát hành: 2008